Close Menu

NEW YORK (360Dx) – NeoGenomics today reported a 4 percent year-over-year increase in its total third quarter revenues, as clinical testing revenues grew less than 1 percent. 

For the three months ending Sept. 30, total revenues rose to $63.1 million from $60.8 million in the year-ago period, but fell short of the consensus Wall Street estimate of $63.9 million. 

Clinical testing revenues inched up to $56.2 million from $55.7 million in Q3 2016, and pharma services revenues rose 38 percent to $6.9 million from $5.0 million a year ago. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.